210 related articles for article (PubMed ID: 10778958)
1. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
Beck FW; Eilender DS; Dandashi MH; Siddiq F; Snell DC; Godmere MA; Al-Katib AM; Mohammad RM
Int J Mol Med; 2004 Jul; 14(1):113-9. PubMed ID: 15202025
[TBL] [Abstract][Full Text] [Related]
5. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
al-Katib A; Mohammad RM; Dan M; Hussein ME; Akhtar A; Pettit GR; Sensenbrenner LL
Exp Hematol; 1993 Jan; 21(1):61-5. PubMed ID: 8093352
[TBL] [Abstract][Full Text] [Related]
6. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
7. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.
Wall NR; Beck FW; Al-Katib AM; Mohammad RM
J Drug Target; 2001; 9(5):329-39. PubMed ID: 11770703
[TBL] [Abstract][Full Text] [Related]
8. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
10. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
[TBL] [Abstract][Full Text] [Related]
11. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study.
Liu KZ; Schultz CP; Mohammad RM; Al-Katib AM; Johnston JB; Mantsch HH
Cancer Lett; 1998 May; 127(1-2):185-93. PubMed ID: 9619876
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells.
Santini V; Gozzini A; Scappini B; Caporale R; Zoccolante A; Rigacci L; Gelardi E; Grossi A; Alterini R; Ferrini PR
Haematologica; 1999 Oct; 84(10):897-904. PubMed ID: 10509037
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.
Saxena A; Viswanathan S; Moshynska O; Tandon P; Sankaran K; Sheridan DP
Am J Hematol; 2004 Jan; 75(1):22-33. PubMed ID: 14695629
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
[TBL] [Abstract][Full Text] [Related]
18. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
19. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
[TBL] [Abstract][Full Text] [Related]
20. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
